NeoGenomics has expanded its partnership with Indica Labs, adopting the HALO AP platform as the cloud-based foundation for its digital…
SimBioSys has secured 510(k) clearance from the FDA for TumorSight Risk, a prognostic tool that estimates breast cancer recurrence risk…
An AI that reads routine tumor slides alongside clinical notes separated two groups of high-risk patients whose five-year outcomes diverged…
The oncology trial matching company joins OpenAI's Select tier to pair frontier models with cancer care workflows.